Amplia Therapeutics Ltd Company Profile

Tackling significant unmet needs in cancer and fibrosis

Amplia Therapeutics Limited is advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis.

  • Company
    Amplia Therapeutics Ltd
  • Website
  • Sector
  • Industry
  • Code
  • Socials

Company Overview

Star icon Promoted

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer immunology and Amplia has a particular development focus in pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF).

Share this profile:

The Right Assets, The Right People And The Right Investors At The Right Time.

Amplia's technology is addressing a multi-billion-dollar market by targeting fibrotic cancer & chronic fibrotic diseases.

Platinum Investment Management and BlueFlag Holdings (an investment vehicle of former Macquarie Group CEO Allan Moss), are recent cornerstone investors in Amplia.

Timing & Expertise

The Amplia team have significant experience commercialising drugs and have recently appointed Nucleus Network to conduct its Phase 1 clinical trials.

Unmet Need

Amplia's technology has been validated by the U.S. FDA by being awarded two Orphan Drug Designations for IPF and Pancreatic Cancer.

ASX presentation

Click here to view the latest presentation

The right opportunity...

Amplia are among the first in the world to explore how FAK could expand the growing multi-billion-dollar checkpoint inhibitor market. The global immune checkpoint inhibitors market was valued at $10,566 million in 2017, and is projected to reach $56,530 million by 2025, registering a CAGR of 20.1% from 2018 to 2025. (Source: Allied Market Research). Historical growth in this market has also been significant (see image).

...being tackled by the right assets...

Amplia's AMP886 and AMP945 are targeting several conditions within both Cancer and Fibrosis, which gives them an opportunity to take 'multiple shots at goal'. Furthermore, early studies have demonstrated that Amplia's molecules are highly differentiated and competitive. AMP945 in particular is believed to be highly focused in what it targets, which could suggest improved safety characteristics in comparison to other FAK assets currently being developed.

...being managed by the right people...

The Amplia board have a significant track record in the development and commercialisation of drugs. A comprehensive list of achievements can be found here, and includes but is not limited to multi-billion-dollar transactions to big-pharma in the U.S. In addition, Amplia's Scientific Advisory Board consists of world leaders in FAK biology, including recent appointment Professor Paul Timpson.
Profile image
Warwick Tong MB ChB MPP GAICD
Non-Executive Chairman
Profile image
John Lambert PhD GAICD
Chief Executive Officer & Managing Director
Profile image
Robert Peach PhD
Independent Non-Executive Director
Profile image
Christopher Burns BSc (Hons) PhD GAICD
Non-Executive Director

....and supported by the right investors...

Platinum Investment Management has participated in Amplia's two most recent capital raises and have became a significant cornerstone investor in Amplia. In addition, BlueFlag Holdings Pty Ltd ("BlueFlag") has also became a substantial holder as a result of the most recent capital raise. BlueFlag is an investment vehicle of Allan Moss who is the former CEO of Macquarie Group Ltd (ASX:MQG) and is widely regarded to be a sophisticated biotechnology investor.

Substantial Shareholder

Click here to view BlueFlag Holdings Pty Ltd Substantial Shareholder Notice.

... at the right time.

Amplia has multiple value accretive milestones mapped out over the next 18 months and is fully funded to execute on its growth plans. After receiving positive results from its pre-clinical toxicology studies for AMP945 Amplia have appointed Nucleus Network to conduct its Phase 1 clinical trial testing. Amplia have also recently been awarded Orphan Drug Designation by the FDA for Idiopathic Pulmonary Fibrosis (IPF) and Pancreatic Cancer bringing further validation to Amplia's technology.
Clock icon Information current at 24 July 2020
This section contains information provided by Amplia Therapeutics Ltd, with the exception of any sections labeled as "risks". Although all due care has been taken, Mawson Graham ("SmallCapInsider") does not warrant the accuracy of the information provided in this section. It is not intended as an offer, invitation solicitation or recommendation with respect to the purchase or sale of any securities. The above information should not be relied upon as the sole representation of any matter that a potential investor should consider in evaluating Amplia Therapeutics Ltd. Its affiliates or any of its directors, agents, officers or employees do not make any representation or warranty, express or implied, as to or endorsement of, the accuracy or completeness of any information, statements, representations or forecasts contained above, and they do not accept any liability for any statement made in, or omitted from, the above. Prospective investors should make their own independent evaluation of an investment in Amplia Therapeutics Ltd. This information may contain forward looking statements concerning Amplia Therapeutics Ltd. Forward-looking statements are not statements of historical fact and actual events and results may differ materially from those described in the forward looking statements as a result of a variety of risks, uncertainties and other factors. Forward-looking statements are inherently subject to business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause the Company’s actual results to differ materially from those expressed or implied in any forward-looking information provided by Amplia Therapeutics Ltd, or on behalf of Amplia Therapeutics Ltd. Forward looking statements are based on Amplia Therapeutics Ltd's beliefs, opinions and estimates. No obligation is assumed to update forward looking statements if these beliefs, opinions and estimates should change or to reflect other future developments.

News Coverage

Current news mentioning Amplia Therapeutics Ltd from top publishers around the web.
Powered by  

Key Announcements

Management comments and explanations on key company announcements.
Need a full list of every announcement? Visit ASX

How do I invest?

Considering investing in Amplia Therapeutics Ltd?
Here's how to get started.
Low Cost Brokerage ASX Cheapest ASX Trading Platform
  1. 1

    Create account

    Open an account with an online broker of your choice. If you do not have an existing broker, consider Vested Equities' A$9.50 flat fee platform.

    Sign up now »
  2. 2

    Search for ASX:ATX

    On your online investment platform search for the stock ticker code ASX:ATX to bring up the company's shares.

  3. 3

    Buy shares

    Place your order however you wish. If you need advice on buying or selling, you should seek the assistance of a full service financial adviser experienced in small cap equities.